The role of PET [18F]FDOPA in evaluating low-grade glioma

Veronica Villani; Carmine M. Carapella; Agostino Chiaravalloti; Irene Terrenato; Francesca Piludu; Antonello Vidiri; Orazio Schillaci; Roberto Floris; Simona Marzi; Alessandra Fabi; Andrea Pace

The role of PET [¹⁸F]FDOPA in evaluating low-grade glioma

Veronica Villani, Carmine M. Carapella, Agostino Chiaravalloti, Irene Terrenato, Francesca Piludu, Antonello Vidiri, Orazio Schillaci, Roberto Floris, Simona Marzi, Alessandra Fabi, Andrea Pace

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: The aim of the present study was to evaluate the prognostic value of 3,4-dihydroxy-6-[¹⁸F]- fluoro-L-phenylalanine ([¹⁸F]-FDOPA) positron-emission tomography (PET) in predicting the risk of radiological progression of disease in patients affected by low-grade glioma. Patients and Methods: Patients affected by grade II glioma were consecutively enrolled in a prospective observational study at the Department of Neurology of Regina Elena National Cancer Institute in Rome, Italy. At enrolment, all patients underwent PET [¹⁸F]-FDOPA and Magnetic Resonance Imaging (MRI), and clinical and radiological assessments with MRI every six months to evaluate the progression of disease. Results: A total of 50 patients affected by grade II glioma (30 males and 20 females) were included in the study. The multivariate analysis showed that standardized uptake value greater than 1.75 and disease duration were independent predictors of disease progression. Conclusion: These findings suggest that the PET [¹⁸F]-FDOPA may play an important prognostic role in evaluation of low-grade glioma.

Original language	English
Pages (from-to)	5117-5122
Number of pages	6
Journal	Anticancer Research
Volume	35
Issue number	9
Publication status	Published - Sep 1 2015

Keywords

Low-grade glioma
PET 18F-FDOPA
Prognostic factors
Progressive disease

ASJC Scopus subject areas

Cancer Research
Oncology

Cite this

The role of PET [¹⁸F]FDOPA in evaluating low-grade glioma. / Villani, Veronica; Carapella, Carmine M.; Chiaravalloti, Agostino; Terrenato, Irene ; Piludu, Francesca ; Vidiri, Antonello; Schillaci, Orazio; Floris, Roberto; Marzi, Simona; Fabi, Alessandra; Pace, Andrea.

In: Anticancer Research, Vol. 35, No. 9, 01.09.2015, p. 5117-5122.

Research output: Contribution to journal › Article › peer-review

@article{994f64aa38a649cba7be0a605e26b823,

title = "The role of PET [18F]FDOPA in evaluating low-grade glioma",

abstract = "Aim: The aim of the present study was to evaluate the prognostic value of 3,4-dihydroxy-6-[18F]- fluoro-L-phenylalanine ([18F]-FDOPA) positron-emission tomography (PET) in predicting the risk of radiological progression of disease in patients affected by low-grade glioma. Patients and Methods: Patients affected by grade II glioma were consecutively enrolled in a prospective observational study at the Department of Neurology of Regina Elena National Cancer Institute in Rome, Italy. At enrolment, all patients underwent PET [18F]-FDOPA and Magnetic Resonance Imaging (MRI), and clinical and radiological assessments with MRI every six months to evaluate the progression of disease. Results: A total of 50 patients affected by grade II glioma (30 males and 20 females) were included in the study. The multivariate analysis showed that standardized uptake value greater than 1.75 and disease duration were independent predictors of disease progression. Conclusion: These findings suggest that the PET [18F]-FDOPA may play an important prognostic role in evaluation of low-grade glioma.",

keywords = "Low-grade glioma, PET 18F-FDOPA, Prognostic factors, Progressive disease",

author = "Veronica Villani and Carapella, {Carmine M.} and Agostino Chiaravalloti and Irene Terrenato and Francesca Piludu and Antonello Vidiri and Orazio Schillaci and Roberto Floris and Simona Marzi and Alessandra Fabi and Andrea Pace",

year = "2015",

month = sep,

day = "1",

language = "English",

volume = "35",

pages = "5117--5122",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "9",

}

TY - JOUR

T1 - The role of PET [18F]FDOPA in evaluating low-grade glioma

AU - Villani, Veronica

AU - Carapella, Carmine M.

AU - Chiaravalloti, Agostino

AU - Terrenato, Irene

AU - Piludu, Francesca

AU - Vidiri, Antonello

AU - Schillaci, Orazio

AU - Floris, Roberto

AU - Marzi, Simona

AU - Fabi, Alessandra

AU - Pace, Andrea

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Aim: The aim of the present study was to evaluate the prognostic value of 3,4-dihydroxy-6-[18F]- fluoro-L-phenylalanine ([18F]-FDOPA) positron-emission tomography (PET) in predicting the risk of radiological progression of disease in patients affected by low-grade glioma. Patients and Methods: Patients affected by grade II glioma were consecutively enrolled in a prospective observational study at the Department of Neurology of Regina Elena National Cancer Institute in Rome, Italy. At enrolment, all patients underwent PET [18F]-FDOPA and Magnetic Resonance Imaging (MRI), and clinical and radiological assessments with MRI every six months to evaluate the progression of disease. Results: A total of 50 patients affected by grade II glioma (30 males and 20 females) were included in the study. The multivariate analysis showed that standardized uptake value greater than 1.75 and disease duration were independent predictors of disease progression. Conclusion: These findings suggest that the PET [18F]-FDOPA may play an important prognostic role in evaluation of low-grade glioma.

AB - Aim: The aim of the present study was to evaluate the prognostic value of 3,4-dihydroxy-6-[18F]- fluoro-L-phenylalanine ([18F]-FDOPA) positron-emission tomography (PET) in predicting the risk of radiological progression of disease in patients affected by low-grade glioma. Patients and Methods: Patients affected by grade II glioma were consecutively enrolled in a prospective observational study at the Department of Neurology of Regina Elena National Cancer Institute in Rome, Italy. At enrolment, all patients underwent PET [18F]-FDOPA and Magnetic Resonance Imaging (MRI), and clinical and radiological assessments with MRI every six months to evaluate the progression of disease. Results: A total of 50 patients affected by grade II glioma (30 males and 20 females) were included in the study. The multivariate analysis showed that standardized uptake value greater than 1.75 and disease duration were independent predictors of disease progression. Conclusion: These findings suggest that the PET [18F]-FDOPA may play an important prognostic role in evaluation of low-grade glioma.

KW - Low-grade glioma

KW - PET 18F-FDOPA

KW - Prognostic factors

KW - Progressive disease

UR - http://www.scopus.com/inward/record.url?scp=84939630466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939630466&partnerID=8YFLogxK

M3 - Article

C2 - 26254416

AN - SCOPUS:84939630466

VL - 35

SP - 5117

EP - 5122

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -

The role of PET [¹⁸F]FDOPA in evaluating low-grade glioma

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this